Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients

Autor: Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Macapinlac HA, Kappadath SC

Publikováno v: Journal of Hepatocellular Carcinoma, Vol Volume 7, Pp 117-131 (2020)

Ajalaya Teyateeti,1,2 Armeen Mahvash,3 James P Long,4 Mohamed E Abdelsalam,3 Rony Avritscher,3 Beth Chasen,1 Ahmed O Kaseb,5 Joshua D Kuban,3 Ravi Murthy,3 Bruno C Odisio,3 Achiraya Teyateeti,6 Homer A Macapinlac,1 S Cheenu Kappadath7 1Department of

Externí odkaz: https://doaj.org/article/dffa5cc11cea4cb9b9d7787ed3ad616e

1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

Autor: Pavel, M.E., Ferone, D., Halperin, D., Myrehaug, S., Herrmann, K., Kunz, P.L., Chasen, B., Capdevila Castillon, J., Tafuto, S., Oh, D-Y., Yoo, C., Falk, S., Halfdanarson, T.R., Folitar, I., Zhang, Y., de Herder, W.W., Singh, S.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S753-S753

Migration of central lines from the superior vena cava to the azygous vein

Autor: Haygood, T.M., Malhotra, K., Ng, C., Chasen, B., McEnery, K.W., Chasen, M.

Publikováno v: In Clinical Radiology 2012 67(1):49-54

O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate

Autor: Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Chaplin, M., Baum, R., Kunz, P., Hobday, T., Oberg, K., Lopera Sierra, M., Kwekkeboom, D., Ruszniewski, P., Krenning, E., Hendifar, A.

Publikováno v: In Annals of Oncology June 2016 27 Supplement 2:ii121-ii121

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Autor: Strosberg, J, El Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, Pl, Kulke, Mh, Jacene, H, Bushnell, D, O'Dorisio, Tm, Baum, Rp, Kulkarni, Hr, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, Jl, Ruszniewski, P, Kwekkeboom, D, Krenning, E, Ansquer, C, Baudin, E, Courbon, F, Giammarile, F, Taieb, D, Scheidhauer, K, Weber, M, Bodei, L, Brianzoni, E, DELLE FAVE, Gianfranco, Chiara Grana, M, Mariani, G, Rindi, G, Severi, S, Azevedo, I, Sundin, A, Al‐nahhas, A, Freemantle, N, Grossman, A, Manoharan, P, Anthony, L, Benson, Ab, Garbus, S, Kulke, M, Kvols, L, Metz, D, Morse, M, Schipper, M, Yao, J.

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Strosberg, J, El-Haddad, G, Wolin, E, Hendifar, A, Yao, J, Chasen, B, Mittra, E, Kunz, P L, Kulke, M H, Jacene, H, Bushnell, D, O'Dorisio, T M, Baum, R P, Kulkarni, H R, Caplin, M, Lebtahi, R, Hobday, T, Delpassand, E, Van Cutsem, E, Benson, A, Srirajaskanthan, R, Pavel, M, Mora, J, Berlin, J, Grande, E, Reed, N, Seregni, E, Öberg, K, Lopera Sierra, M, Santoro, P, Thevenet, T, Erion, J L, Ruszniewski, P, Kwekkeboom, D, Krenning, E 2017, ' Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors ', New England Journal of Medicine, vol. 376, no. 2, pp. 125-135 . https://doi.org/10.1056/NEJMoa1607427
New England Journal of Medicine, 376(2), 125-135. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Background: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d16eb685cdcea5fc492f1baf8bef39c3
https://doi.org/10.1056/nejmoa1607427